Xiaomin Ling

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

M. Zhang, Zhihai Wu, Bingliang Chen, 2021, Nature Communications.

Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance

W. Liang, Jincun Zhao, Junjian Liu, 2022, The Journal of clinical investigation.

IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells

Yaning Li, Min Wu, Zhihai Wu, 2023, Nature Cancer.